Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
27 févr. 2024 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Brooke Eby, ALS Patient and Advocate, to deliver Keynote Address at 2024 MDA Clinical & Scientific Conference
15 févr. 2024 09h00 HE
|
Muscular Dystrophy Association
New York, Feb. 15, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Brooke Eby will be the keynote speaker at the 2024 MDA Clinical & Scientific...
Muscular Dystrophy Association Opens Registration for Campers and Volunteers for MDA Summer Camp 2024 to be Held at Locations Nationwide
22 janv. 2024 09h00 HE
|
Muscular Dystrophy Association
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for both campers and volunteers for its MDA Summer Camp program. MDA...
Muscular Dystrophy Association Announces Acosta Group’s Historic $100 Million Fundraising Milestone
21 déc. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, Dec. 21, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today that long-term partner Acosta Group has reached a historic $100 million milestone in fundraising...
Revolutionizing Scoliosis Treatment: Dr. Zeke Harkleroad Achieves Remarkable Results Through Groundbreaking Technology
19 déc. 2023 10h00 HE
|
Bee Caves Scoliosis and Chiropractic
AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Dr. Zeke Harkleroad, a leading authority in spinal health and wellness, is proud to announce the launch of a revolutionary technology that has been...
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
18 déc. 2023 06h30 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
15 déc. 2023 09h05 HE
|
Biogen Inc.
Friedreich’s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen’s growing portfolio in rare diseases and focus on addressing unmet needs of...
Muscular Dystrophy Association Launches Holiday Retail Campaign in Thousands of Retail Locations Nationwide
01 nov. 2023 09h00 HE
|
Muscular Dystrophy Association
New York, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today launched its largest Holiday Retail Campaign to fundraise in thousands of retail locations nationwide from...
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
30 oct. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Muscular Dystrophy Association-Supported Drug AGAMREE® (vamorolone) Approved for the Treatment of Duchenne Muscular Dystrophy by the FDA
26 oct. 2023 16h24 HE
|
Muscular Dystrophy Association
New York, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) approval of AGAMREE® (vamorolone), a structurally unique...